bioAffinity's CyPath® Lung Test Validated in High-Risk Patient Case Study

Event summary

  • bioAffinity Technologies published a case study demonstrating CyPath® Lung's clinical utility in a 59-year-old high-risk patient with multiple pulmonary nodules.
  • The test returned a negative result, supporting a six-month CT surveillance schedule consistent with Lung-RADS 3 guidelines.
  • CyPath® Lung achieved 92% sensitivity, 87% specificity, and 88% accuracy in detecting lung cancer in high-risk patients with small indeterminate nodules.
  • The case study highlights CyPath® Lung's role in reducing patient anxiety and potentially avoiding invasive procedures on benign nodules.

The big picture

The case study underscores the growing demand for noninvasive diagnostics in lung cancer, particularly for high-risk patients with ambiguous imaging results. As healthcare systems prioritize early detection and cost-effective surveillance, bioAffinity's CyPath® Lung positions itself as a key tool in reducing unnecessary procedures and alleviating patient anxiety. The test's high accuracy metrics could accelerate its adoption in clinical guidelines, though competition in the diagnostic space remains intense.

What we're watching

Clinical Adoption
How quickly CyPath® Lung gains traction among pulmonologists managing high-risk patients with indeterminate nodules.
Regulatory Pathway
Whether bioAffinity can secure broader regulatory approvals to expand CyPath® Lung's market reach.
Competitive Positioning
The pace at which bioAffinity can differentiate CyPath® Lung from emerging diagnostic technologies in lung cancer screening.

Related topics

Biotechnology